Search
Serina Therapeutics Inc
SERAdd to Watchlist
1.945USD
+0.005+0.26%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
28.98MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.26%
5 Days
+5.71%
1 Month
+7.46%
6 Months
+1.67%
Year to Date
+1.67%
1 Year
-67.69%
Key Figures
1.940Open
2.000High
73.26KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.49%Turnover Ratio
1.940Prev. Close
1.920Low
92.36KTurnover
LossP/E Static
2.28P/B
0.00%Div Yield TTM
-125.13%ROA
7.92052wk High
1.25Volume Ratio
-11.14MNet Profit
14.90MShares
-1.9647EPS TTM
1.20Beta
-296.12%ROE
1.22052wk Low
4.13%Amplitude
100.00%Gross Margin
28.98MMarket Cap
1.79Reward/Risk
5.72%Risk Rate
TradingKey Stock Score of Serina Therapeutics Inc
Currency: USD Updated: 2026-07-01Key Insights
Serina Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 201 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 11.33.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Serina Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Serina Therapeutics Inc Highlights
StrengthsRisks
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Growing
The company is in a growing phase, with the latest annual income totaling USD 130.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 130.00K.
Fairly Valued
The company’s latest PE is -0.98, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.62M shares, increasing 40.88% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
11.333
Target Price
+484.19%
Upside Space
Serina Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Serina Therapeutics Inc Info
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Ticker SymbolSER
CompanySerina Therapeutics Inc
CEOLedger (Steven)
Websitehttps://serinatherapeutics.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52358.200
+103.900 (+0.20%)
29957.400
+158.100 (+0.53%)
7499.800
+24.300 (+0.33%)
14988.000
-367.000 (-2.39%)
69819.000
+334.000 (+0.48%)
6298.200
+22.800 (+0.36%)
67.661
-0.307 (-0.45%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4055.170
+24.400 (+0.60%)
FAQs
What is the current price of Serina Therapeutics Inc (SER)?
The current price of Serina Therapeutics Inc (SER) is 1.95.
What is the symbol of Serina Therapeutics Inc?
The ticker symbol of Serina Therapeutics Inc is SER.
What is the 52-week high of Serina Therapeutics Inc?
The 52-week high of Serina Therapeutics Inc is 7.92.
What is the 52-week low of Serina Therapeutics Inc?
The 52-week low of Serina Therapeutics Inc is 1.22.
What is the market capitalization of Serina Therapeutics Inc?
The market capitalization of Serina Therapeutics Inc is 28.98M.
Is Serina Therapeutics Inc (SER) currently rated as Buy, Hold, or Sell?
According to analysts, Serina Therapeutics Inc (SER) has an overall rating of STRONG BUY, with a price target of 11.33.
What is the Earnings Per Share (EPS TTM) of Serina Therapeutics Inc (SER)?
The Earnings Per Share (EPS TTM) of Serina Therapeutics Inc (SER) is -1.88.